Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round. The investment was led by renowned venture capital firms Atlas Venture and Sofinnova Partners, along with participation from Forbion and Longwood Fund.

AAVantgarde Bio has established itself as an international leader in the field of biotechnology research. The company has developed two proprietary Adeno-Associated Viral (AAV) vector platforms, aiming to overcome the gene therapy cargo capacity limitations associated with traditional AAV vectors.

The groundbreaking platform developed by AAVantgarde Bio is currently undergoing clinical validation for two Inherited Retinal Diseases: Usher1B and Stargardt disease. By addressing the gene therapy cargo capacity limitations of AAV vectors, AAVantgarde Bio's platform holds the potential to revolutionize treatment options in a wide range of disease areas.

Dr. Natalia Misciattelli Mocenigo Soranzo, Founder of AAVantgarde Bio, expressed her gratitude for the support received from investors and shared her excitement about the company's future prospects. She stated, "We are thrilled to have secured this significant funding, which will propel our mission of advancing gene therapy and bringing hope to patients worldwide. This investment will allow us to continue pushing the boundaries of biotechnology and expanding our platform to address a multitude of genetic diseases."